The Management of Panic Disorder
J Clin Psychiatry 2002;63(suppl 14):17-21
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
The evidence for benzodiazepines in panic disorder is compelling; along with the selective serotonin
reuptake inhibitors (SSRIs), they are a standard treatment for panic and other anxiety disorders. However,
extended-release formulations of these agents may prove to be as effective as the immediate-release
formulations, and extended-release agents have clinical benefits that may make them more
attractive treatments than the currently available, shorter-acting benzodiazepines. Because of their
longer duration of action, extended-release benzodiazepines can protect against breakthrough anxiety
and need to be taken only once or twice a day, which may improve compliance in some patients. Because
the other standard treatments of panic disorder, the SSRIs, have a slow onset of action, adding an
extended-release benzodiazepine to the treatment regimen for the initial 6 to 8 weeks could serve as an
effective bridge until the desired SSRI effect is realized.